Business Description
Trevi Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US89532M1018
Total Employee Number:
34Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 527.06 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 9.9 | |||||
3-Year EPS without NRI Growth Rate | 10.6 | |||||
3-Year FCF Growth Rate | 10.8 | |||||
3-Year Book Growth Rate | -7.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -31.84 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.78 | |||||
9-Day RSI | 43.89 | |||||
14-Day RSI | 45.42 | |||||
3-1 Month Momentum % | 34.6 | |||||
6-1 Month Momentum % | 45.12 | |||||
12-1 Month Momentum % | 159.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 37.28 | |||||
Quick Ratio | 37.28 | |||||
Cash Ratio | 36.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.9 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -23.99 | |||||
ROA % | -23 | |||||
ROIC % | -1230.51 | |||||
3-Year ROIIC % | 473.22 | |||||
ROC (Joel Greenblatt) % | -6033.66 | |||||
ROCE % | -26.03 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.65 | |||||
Price-to-Tangible-Book | 7.64 | |||||
EV-to-EBIT | -38.54 | |||||
EV-to-EBITDA | -38.63 | |||||
EV-to-Forward-Revenue | 90.47 | |||||
EV-to-FCF | -40.52 | |||||
| Price-to-Net-Current-Asset-Value | 7.78 | |||||
| Price-to-Net-Cash | 7.92 | |||||
Earnings Yield (Greenblatt) % | -2.59 | |||||
FCF Yield % | -2.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRVI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Trevi Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.34 | ||
| Beta | -0.4817 | ||
| 3-Year Sharpe Ratio | 1.1 | ||
| 3-Year Sortino Ratio | 2.91 | ||
| Volatility % | 53.66 | ||
| 14-Day RSI | 45.42 | ||
| 14-Day ATR ($) | 0.816581 | ||
| 20-Day SMA ($) | 17.77625 | ||
| 12-1 Month Momentum % | 159.34 | ||
| 52-Week Range ($) | 6.93 - 20.22 | ||
| Shares Outstanding (Mil) | 142.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Trevi Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Trevi Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 67 days | ||
| https://ccdbwebprod.dcc8fc7.eas.morningstar.com/CCDB/Files/678376679.html | 2026-09-15 16:50 | In 9 days | ||
| Guidance call for 2026 | 2026-09-10 10:55 | In 4 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 18.65 (-1.84%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 18.65 (-1.84%) | ||
| General meeting for 2026 | 2026-06-03 11:00 | 13.50 (-3.02%) | ||
| Guidance call for 2026 | 2026-05-12 17:15 | 14.88 (+2.62%) | ||
| Trevi Therapeutics Investor and Analyst Day | 2026-05-07 10:00 | 14.26 (+0.85%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 14.38 (+4.35%) |
Show
Entries
Trevi Therapeutics Inc Frequently Asked Questions
What is Trevi Therapeutics Inc(TRVI)'s stock price today?
The current price of TRVI is $17.27. The 52 week high of TRVI is $20.22 and 52 week low is $6.93.
When is next earnings date of Trevi Therapeutics Inc(TRVI)?
The next earnings date of Trevi Therapeutics Inc(TRVI) is 2026-11-13 Est..
Does Trevi Therapeutics Inc(TRVI) pay dividends? If so, how much?
Trevi Therapeutics Inc(TRVI) does not pay dividend.
Press Release
Articles on Trevi Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers